Magne BÃ¸rset

List of Publications by Year
in descending order

93	4,059	117453 34	123241 61
papers	citations	h-index	g-index
95	95	95	3970
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood, 2002, 100, 3002-3007.	0.6	227
2	Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood, 2000, 95, 388-392.	0.6	210
3	Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma. Blood, 1998, 91, 806-812.	0.6	192
4	Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood, 2001, 98, 2269-2271.	0.6	158
5	Interleukin-21 is a growth and survival factor for human myeloma cells. Blood, 2002, 99, 3756-3762.	0.6	152
6	HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood, 2007, 109, 3024-3030.	0.6	152
7	Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia, 2006, 20, 1138-1144.	3.3	139
8	Concomitant Expression of Hepatocyte Growth Factor/Scatter Factor and the Receptor c-MET in Human Myeloma Cell Lines. Journal of Biological Chemistry, 1996, 271, 24655-24661.	1.6	122
9	Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood, 2001, 97, 516-522.	0.6	114
10	Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene, 2004, 23, 3024-3032.	2.6	113
11	Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood, 2000, 96, 2528-2536.	0.6	103
12	Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. Blood, 1999, 94, 3883-3888.	0.6	99
13	High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood, 2000, 96, 3139-3146.	0.6	91
14	Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood, 2008, 111, 806-815.	0.6	90
15	A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells. Clinical Cancer Research, 2004, 10, 6686-6694.	3.2	83
16	Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. British Journal of Haematology, 2005, 128, 210-217.	1.2	81
17	Serglycin Constitutively Secreted by Myeloma Plasma Cells Is a Potent Inhibitor of Bone Mineralization in Vitro. Journal of Biological Chemistry, 2006, 281, 35116-35128.	1.6	81
18	Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2001, 30, 229-234.	0.6	71

#	Article	IF	Citations
19	Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood, 2002, 100, 3925-3929.	0.6	71
20	Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. , 2020, 8, e000610.		70
21	Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. Oncogene, 2011, 30, 3198-3206.	2.6	66
22	TNF and ILâ€6 are potent growth factors for OHâ€2, a novel human myeloma cell line. European Journal of Haematology, 1994, 53, 31-37.	1.1	64
23	Syndecan-1 in B lymphoid malignancies. Annals of Hematology, 2002, 81, 125-135.	0.8	63
24	Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency Mice. Journal of Bone and Mineral Research, 1999, 14, 256-263.	3.1	62
25	Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica, 2004, 89, 174-82.	1.7	56
26	Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica, 2017, 102, 1266-1272.	1.7	51
27	Lack of ILâ€1 secretion from human myeloma cells highly purified by immunomagnetic separation. British Journal of Haematology, 1993, 85, 446-451.	1.2	50
28	Matrix Metalloproteinases in Multiple Myeloma. Leukemia and Lymphoma, 2000, 37, 273-281.	0.6	48
29	Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. British Journal of Haematology, 2002, 119, 672-676.	1.2	48
30	Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: Implications for multiple myeloma. European Journal of Immunology, 2011, 41, 437-449.	1.6	48
31	câ€Met signaling promotes ILâ€6â€induced myeloma cell proliferation. European Journal of Haematology, 2009, 82, 277-287.	1.1	44
32	Preoperative traction in patients with hip fractures. Injury, 1992, 23, 242-244.	0.7	40
33	Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica, 2008, 93, 619-622.	1.7	40
34	Antiâ€câ€<scp>MET</scp> Nanobody^{Â®} â€“ a new potential drug in multiple myeloma treatment. European Journal of Haematology, 2013, 91, 399-410.	1.1	40
35	Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia, 2012, 26, 1073-1080.	3.3	39
36	Bronchoalveolar Lavage Fluid IFN-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">Î³</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:mrow></mr Cells and Regulatory T Cells in Pulmonary Sarcoidosis. Mediators of Inflammation, 2014, 2014, 1-9.	1.4	36

#	Article	IF	Citations
37	Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica, 2005, 90, 479-88.	1.7	35
38	The Role of Hepatocyte Growth Factor and its Receptor C-Met in Multiple Myeloma and Other Blood Malignancies. Leukemia and Lymphoma, 1999, 32, 249-256.	0.6	34
39	Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. British Journal of Haematology, 1999, 106, 28-34.	1.2	34
40	Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. British Journal of Haematology, 2000, 109, 815-822.	1.2	34
41	Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. European Journal of Haematology, 2008, 81, 380-383.	1.1	32
42	High expression of <i>BCL3</i> in human myeloma cells is associated with increased proliferation and inferior prognosis. European Journal of Haematology, 2009, 82, 354-363.	1.1	32
43	<i>MYC</i>amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy. Oncotarget, 2015, 6, 22698-22705.	0.8	27
44	The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells. Oncotarget, 2016, 7, 27295-27306.	0.8	27
45	HGF and IGF-1 synergize with SDF-1Î± in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Experimental Hematology, 2013, 41, 646-655.	0.2	26
46	Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration. Journal of Translational Medicine, 2016, 14, 71.	1.8	26
47	Heparan Sulfate Regulates Targeting of Syndecan-1 to a Functional Domain on the Cell Surface. Journal of Biological Chemistry, 2003, 278, 12888-12893.	1.6	25
48	Decorin is downâ€regulated in multiple myeloma and <scp>MGUS</scp> bone marrow plasma and inhibits <scp>HGF</scp>â€induced myeloma plasma cell viability and migration. European Journal of Haematology, 2013, 91, 196-200.	1.1	25
49	PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget, 2018, 9, 32024-32035.	0.8	25
50	THE ROLE OF THE TWO TNF RECEPTORS IN PROLIFERATION, NF-ÎºB ACTIVATION AND DISCRIMINATION BETWEEN TNF AND LTÎ±SIGNALLING IN THE HUMAN MYELOMA CELL LINE OH-2. Cytokine, 1996, 8, 430-438.	1.4	23
51	Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Nonâ€“small-cell Lung Cancer. Translational Oncology, 2020, 13, 17-24.	1.7	23
52	Apoptosis, proliferation and NFâ€ÎºB activation induced by agonistic Fas antibodies in the human myeloma cell line OHâ€2: amplification of Fasâ€mediated apoptosis by tumor necrosis factor. European Journal of Haematology, 1999, 63, 345-353.	1.1	21
53	A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells. Journal of Biomolecular Screening, 2013, 18, 637-646.	2.6	21
54	Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. British Journal of Haematology, 1999, 105, 641-647.	1.2	20

#	Article	IF	Citations
55	Phosphatase of regenerating liverâ€3 regulates cancer cell metabolism in multiple myeloma. FASEB Journal, 2021, 35, e21344.	0.2	19
56	Hepatocyte growth factor reverses the TGF-Î²-induced growth inhibition of CCL-64 cells. Journal of Immunological Methods, 1996, 189, 59-64.	0.6	17
57	Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3. Molecular Cancer Research, 2017, 15, 69-77.	1.5	17
58	Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma. Blood, 1998, 91, 806-812.	0.6	17
59	Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance. Oncotarget, 2018, 9, 3549-3561.	0.8	17
60	Role of hepatocyte growth factor and its receptorc-met in multiple myeloma. Medical Oncology, 1998, 15, 145-153.	1.2	16
61	OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus. Leukemia Research, 2009, 33, 1670-1677.	0.4	16
62	Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters. European Journal of Haematology, 2011, 87, 394-399.	1.1	16
63	Bone Disease in Multiple Myeloma. Medical Oncology, 2006, 23, 431-442.	1.2	14
64	Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Acta Diabetologica, 1998, 35, 77-80.	1.2	13
65	Why do myeloma patients have bone disease? A historical perspective. Blood Reviews, 2020, 41, 100646.	2.8	13
66	Immunohistochemical analysis of hepatocyte growth factor and câ€Met in plasma cell disease. Histopathology, 2012, 60, 443-451.	1.6	12
67	Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients. Biomarker Research, 2014, 2, 8.	2.8	12
68	Targeting phosphoglycerate dehydrogenase in multiple myeloma. Experimental Hematology and Oncology, 2021, 10, 3.	2.0	12
69	FGFR3 is expressed and is important for survival in INAâ€6, a human myeloma cell line without a t(4;14). European Journal of Haematology, 2009, 83, 471-476.	1.1	11
70	VOLIN and KJONâ€"Two novel hyperdiploid myeloma cell lines. Genes Chromosomes and Cancer, 2016, 55, 890-901.	1.5	11
71	Protein tyrosine phosphatases in multiple myeloma. Cancer Letters, 2021, 501, 105-113.	3.2	11
72	Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro. Journal of Hematology and Oncology, 2016, 9, 75.	6.9	10

#	Article	IF	Citations
73	Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration. Experimental Hematology and Oncology, 2018, 7, 8.	2.0	10
74	Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood, 2000, 96, 2528-2536.	0.6	10
75	Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions. Cancers, 2021, 13, 1788.	1.7	9
76	PRLâ€•3 induces a positive signaling circuit between glycolysis and activation of STAT1/2. FEBS Journal, 2021, 288, 6700-6715.	2.2	9
77	Comparison of the effects of 2-chlorodeoxyadenosine and melphalan on myeloma cell lines. Leukemia Research, 1996, 20, 155-160.	0.4	8
78	Raised Serum Levels of Syndecan-1 (CD138), in a Case of Acute Idiopathic Systemic Capillary Leak Syndrome (SCLS) (Clarksonâ€™s Disease). American Journal of Case Reports, 2018, 19, 176-182.	0.3	8
79	Identification of New Targets for Therapy of Osteolytic Bone Disease in Multiple Myeloma. Current Drug Targets, 2005, 6, 701-711.	1.0	6
80	Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression. Genes Chromosomes and Cancer, 2015, 54, 692-701.	1.5	5
81	Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. Blood, 1999, 94, 3883-3888.	0.6	5
82	High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood, 2000, 96, 3139-3146.	0.6	5
83	Inhibition of Cytosolic Phospholipase A2Î± Induces Apoptosis in Multiple Myeloma Cells. Molecules, 2021, 26, 7447.	1.7	5
84	Mn²⁺ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGFâ€•1, and SDFâ€•1Î±. European Journal of Haematology, 2008, 81, 437-447.	1.1	4
85	Phosphatases of regenerating liver are key regulators of metabolism in cancer cells â€“ role of Serine/Glycine metabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 2022, 25, 50-55.	1.3	4
86	Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?. Frontiers in Immunology, 2021, 12, 636375.	2.2	3
87	Highly expressed genes in multiple myeloma cells â€“ what can they tell us about the disease?. European Journal of Haematology, 2022, 109, 31-40.	1.1	3
88	Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer. PLoS ONE, 2017, 12, e0189000.	1.1	2
89	Immunosuppressive adenosine - a novel treatment target for multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e137-e138.	0.2	0
90	IL-6 and IGF-1 Act in Synergy with HGF in Myeloma Cells by Modulating the Ras-MAPK Pathway.. Blood, 2007, 110, 4793-4793.	0.6	0

#	Article	IF	Citations
91	A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells. Blood, 2012, 120, 1373-1373.	0.6	0
92	The Serine Protease Matriptase Acts As a Tumour Suppressor in Multiple Myeloma. Blood, 2020, 136, 14-14.	0.6	0
93	Skeletal tissue remodeling in multiple myeloma. Haematologica, 2006, 91, 147b.	1.7	0